1Craig WA. Pharmacokinetic/phannacodynamic parameters :rationale for antibacterial dosing of mice and men [ J ]. Clin Infect Dis, 1998,26 : 1 - 12.
2Burkhardt O, Derendorf H, Welte T. Ertapenem : the new carbapenem 5 years after first FDA licensing for clinical practice [ J ]. Expert Opin Pharmacother,2007,8 (2) :237 - 256.
3Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with gram-negative bacilli bacteraemia [ J ]. J Pharm Pharmacol, 2002, 54 : 1693 - 1696.
4Sader HS, Hsiung A, Fritsche TR, et al. Comparative activities of eefepime and piperacillin/tazobactam tested against a global collection of Eschefiehia coli and Klebsiella spp. with an ESBL phenotype[ J]. Diagn Mierobiol Infeet Dis 2007,57:341 -344.
5Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of mempenem 0.5 and 2 g every 8 hours as a 3-hour infusion [ J ]. Pharmacotherapy 2003,23:988 - 991.
7Burkhardt O, Majcher-preszynaka J, Borner K, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery[J]. J Clin Pharmaeo1,2005 ,45 :659 - 665.
8Burkhardt O, Majcher-preszynaka J, Bomer K, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery [ J ]. Clin Mierobiol Infect, 2005,11 ( Suppl 2) :275.
9Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intraabdominal infections:observations from two randomized comparative clinical trials of ertapenem therapy [ J ]. Eur J Clin Microbiol Infect Dis 2005,24:443 -449.
10Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenemcilastatin for treatment of nosocomial pneumonia in intensive care unit patients : a multicenter, evaluatorblind, prospective, randomized study[ J]. Antimicrob Agents Chemother,2003,11:3442 - 3447.
